[Place of recombinant activated factor VII in the treatment of severe haemorrhage in paediatric patients].
Veyckemans
F
F
Service d'Anesthésiologie, Cliniques Universitaires St-Luc, 1200 Bruxelles, Belgique. francis.veyckemans@uclouvain.be
D002648:Child; D005167:Factor VII / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D005168:Factor VII Deficiency / Q000097:blood / Q000188:drug therapy; D006467:Hemophilia A / Q000097:blood / Q000188:drug therapy; D006470:Hemorrhage / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D011994:Recombinant Proteins / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D012306:Risk; D013921:Thrombocytopenia / Q000151:congenital / Q000188:drug therapy
D011994:Recombinant Proteins; D005167:Factor VII